glycine has been researched along with Lymphoma in 24 studies
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we demonstrate in an in vivo transgenic model in which atorvastatin reverses and prevents the onset of MYC-induced lymphomagenesis, but fails to reverse or prevent tumorigenesis in the presence of constitutively activated K-Ras (G12D)." | 7.74 | Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. ( Chang, M; Chen, J; Elchuri, S; Fan, AC; Felsher, DW; Goldstein, MJ; Mitchell, DJ; Nolan, GP; Perez, OD; Shachaf, CM; Sharpe, O; Shirer, AE; Steinman, L; Youssef, S, 2007) |
| "Oral administration of forphenicinol, S-2-(3-hydroxy-4-hydroxymethylphenyl)glycine, inhibited the growth of EL4 lymphoma by both pre- and posttreatment." | 7.67 | Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4. ( Iizuka, H; Ishizuka, M; Naito, K; Okura, A; Takeuchi, T; Umezawa, H, 1987) |
| "gov identifier NCT01454076) assessed the relative bioavailability of capsule B in reference to capsule A in adult patients with advanced solid tumors or lymphoma." | 6.87 | A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. ( Bessudo, A; Gupta, N; Hanley, MJ; Nemunaitis, J; O'Neil, BH; Sharma, S; van de Velde, H; Venkatakrishnan, K; Wang, B, 2018) |
| "Data were pooled from 226 adult patients with multiple myeloma, lymphoma or solid tumours in four phase 1 studies, in which ixazomib dosing (oral/intravenous, once/twice weekly) was based on BSA." | 3.81 | Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. ( Esseltine, DL; Gupta, N; Hui, AM; Venkatakrishnan, K; Zhao, Y, 2015) |
| "The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma." | 3.76 | Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. ( Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L, 2010) |
| " Here, we demonstrate in an in vivo transgenic model in which atorvastatin reverses and prevents the onset of MYC-induced lymphomagenesis, but fails to reverse or prevent tumorigenesis in the presence of constitutively activated K-Ras (G12D)." | 3.74 | Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. ( Chang, M; Chen, J; Elchuri, S; Fan, AC; Felsher, DW; Goldstein, MJ; Mitchell, DJ; Nolan, GP; Perez, OD; Shachaf, CM; Sharpe, O; Shirer, AE; Steinman, L; Youssef, S, 2007) |
| "Oral administration of forphenicinol, S-2-(3-hydroxy-4-hydroxymethylphenyl)glycine, inhibited the growth of EL4 lymphoma by both pre- and posttreatment." | 3.67 | Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4. ( Iizuka, H; Ishizuka, M; Naito, K; Okura, A; Takeuchi, T; Umezawa, H, 1987) |
| "gov identifier NCT01454076) assessed the relative bioavailability of capsule B in reference to capsule A in adult patients with advanced solid tumors or lymphoma." | 2.87 | A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. ( Bessudo, A; Gupta, N; Hanley, MJ; Nemunaitis, J; O'Neil, BH; Sharma, S; van de Velde, H; Venkatakrishnan, K; Wang, B, 2018) |
| "Lymphoma is a heterogeneous group of cancer, where the central roles in pathogenesis play immune evasion and dysregulation of multiple signaling pathways." | 2.72 | Heat Shock Proteins in Lymphoma Immunotherapy. ( Albakova, Z; Mangasarova, Y; Sapozhnikov, A, 2021) |
| " In contrast, dosing with 60 mg/kg of CW252053 produced a cure rate against tumor growth of 37." | 1.31 | In vivo antitumor efficacy of CW252053, a folate-based thymidylate synthase inhibitor. ( Baek, DJ; Ha, JR; Oh, SW, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (41.67) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ishizaki, J | 1 |
| Nakano, C | 1 |
| Kitagawa, K | 1 |
| Suga, Y | 1 |
| Sai, Y | 1 |
| O'Connor, KM | 1 |
| Das, AB | 1 |
| Winterbourn, CC | 1 |
| Hampton, MB | 1 |
| Albakova, Z | 1 |
| Mangasarova, Y | 1 |
| Sapozhnikov, A | 1 |
| Meloni, F | 1 |
| Satta, G | 1 |
| Padoan, M | 1 |
| Montagna, A | 1 |
| Pilia, I | 1 |
| Argiolas, A | 1 |
| Piro, S | 1 |
| Magnani, C | 1 |
| Gambelunghe, A | 1 |
| Muzi, G | 1 |
| Ferri, GM | 1 |
| Vimercati, L | 1 |
| Zanotti, R | 1 |
| Scarpa, A | 1 |
| Zucca, M | 1 |
| De Matteis, S | 1 |
| Campagna, M | 1 |
| Miligi, L | 1 |
| Cocco, P | 1 |
| Maddocks, ODK | 1 |
| Athineos, D | 1 |
| Cheung, EC | 1 |
| Lee, P | 1 |
| Zhang, T | 1 |
| van den Broek, NJF | 1 |
| Mackay, GM | 1 |
| Labuschagne, CF | 1 |
| Gay, D | 1 |
| Kruiswijk, F | 1 |
| Blagih, J | 1 |
| Vincent, DF | 1 |
| Campbell, KJ | 1 |
| Ceteci, F | 1 |
| Sansom, OJ | 1 |
| Blyth, K | 1 |
| Vousden, KH | 1 |
| Hanley, MJ | 2 |
| Gupta, N | 3 |
| Venkatakrishnan, K | 3 |
| Bessudo, A | 2 |
| Sharma, S | 2 |
| O'Neil, BH | 1 |
| Wang, B | 2 |
| van de Velde, H | 1 |
| Nemunaitis, J | 2 |
| Guan, J | 1 |
| Gluckman, P | 1 |
| Yang, P | 1 |
| Krissansen, G | 1 |
| Sun, X | 1 |
| Zhou, Y | 1 |
| Wen, J | 1 |
| Phillips, G | 1 |
| Shorten, PR | 1 |
| McMahon, CD | 1 |
| Wake, GC | 1 |
| Chan, WH | 1 |
| Thomas, MF | 1 |
| Ren, A | 1 |
| Moon, S | 1 |
| Liu, DX | 1 |
| Zhao, Y | 1 |
| Hui, AM | 2 |
| Esseltine, DL | 1 |
| Kupperman, E | 1 |
| Lee, EC | 1 |
| Cao, Y | 1 |
| Bannerman, B | 1 |
| Fitzgerald, M | 1 |
| Berger, A | 1 |
| Yu, J | 1 |
| Yang, Y | 1 |
| Hales, P | 1 |
| Bruzzese, F | 1 |
| Liu, J | 1 |
| Blank, J | 1 |
| Garcia, K | 1 |
| Tsu, C | 1 |
| Dick, L | 1 |
| Fleming, P | 1 |
| Yu, L | 1 |
| Manfredi, M | 1 |
| Rolfe, M | 1 |
| Bolen, J | 1 |
| Rajan, A | 1 |
| Kelly, RJ | 1 |
| Trepel, JB | 1 |
| Kim, YS | 1 |
| Alarcon, SV | 1 |
| Kummar, S | 1 |
| Gutierrez, M | 1 |
| Crandon, S | 1 |
| Zein, WM | 1 |
| Jain, L | 1 |
| Mannargudi, B | 1 |
| Figg, WD | 1 |
| Houk, BE | 1 |
| Shnaidman, M | 1 |
| Brega, N | 1 |
| Giaccone, G | 1 |
| KIT, S | 5 |
| GRAHAM, OL | 2 |
| SARTORELLI, AC | 1 |
| BIEBER, AL | 1 |
| CHANG, PK | 1 |
| FISCHER, GA | 1 |
| FARBER, E | 1 |
| GREENBERG, DM | 2 |
| Shachaf, CM | 1 |
| Perez, OD | 1 |
| Youssef, S | 1 |
| Fan, AC | 1 |
| Elchuri, S | 1 |
| Goldstein, MJ | 1 |
| Shirer, AE | 1 |
| Sharpe, O | 1 |
| Chen, J | 1 |
| Mitchell, DJ | 1 |
| Chang, M | 1 |
| Nolan, GP | 1 |
| Steinman, L | 1 |
| Felsher, DW | 1 |
| Fox, BW | 1 |
| Fox, M | 1 |
| Kien, CL | 1 |
| Camitta, BM | 1 |
| Oh, SW | 1 |
| Ha, JR | 1 |
| Baek, DJ | 1 |
| Reynolds, JV | 1 |
| Daly, JM | 1 |
| Shou, J | 1 |
| Sigal, R | 1 |
| Ziegler, MM | 1 |
| Naji, A | 1 |
| Okura, A | 1 |
| Naito, K | 1 |
| Iizuka, H | 1 |
| Ishizuka, M | 1 |
| Takeuchi, T | 1 |
| Umezawa, H | 1 |
| Clive, D | 1 |
| Flamm, WG | 1 |
| Machesko, MR | 1 |
| Bernheim, NJ | 1 |
| Ozer, HL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma[NCT01454076] | Phase 1 | 112 participants (Actual) | Interventional | 2011-11-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | nanogram*hour per milliliter (ng*hr/mL)] (Geometric Mean) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 551.985 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 1148.778 |
| Arm 2: Ixazomib 4 mg Capsule A | 1284.079 |
| Arm 2: Ixazomib 4 mg Capsule B | 1334.659 |
| Arm 3: Ixazomib 4 mg Fasted | 1465.979 |
| Arm 3: Ixazomib 4 mg Fed | 998.698 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 231.527 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 613.112 |
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hours[hrs])post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 38.975 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 39.250 |
| Arm 2: Ixazomib 4 mg Capsule A | 61.866 |
| Arm 2: Ixazomib 4 mg Capsule B | 71.949 |
| Arm 3: Ixazomib 4 mg Fasted | 77.001 |
| Arm 3: Ixazomib 4 mg Fed | 22.752 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 25.706 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 37.245 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45
| Intervention | participants (Number) |
|---|---|
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 0 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 0 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 0 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 0 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 0 |
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | hours (Median) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 1.090 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 1.500 |
| Arm 2: Ixazomib 4 mg Capsule A | 1.290 |
| Arm 2: Ixazomib 4 mg Capsule B | 1.250 |
| Arm 3: Ixazomib 4 mg Fasted | 1.020 |
| Arm 3: Ixazomib 4 mg Fed | 4.000 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 1.450 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 1 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45)
| Intervention | participants (Number) | |
|---|---|---|
| TEAEs | SAEs | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 29 | 12 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 20 | 5 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 24 | 12 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 18 | 3 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 21 | 10 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45
| Intervention | participants (Number) | ||
|---|---|---|---|
| Blood and lymphatic system disorders | Investigations | Metabolism and nutrition disorders | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 11 | 10 | 22 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 7 | 5 | 12 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 9 | 11 | 13 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 2 | 4 | 6 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 1 | 5 | 6 |
Best overall response for a participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (<) 10 millimeter [mm]). No new lesions. Partial response (PR) was defined as greater than or equal to (>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, Progressive Disease (PD). An increase of >=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest) represents PD. (NCT01454076)
Timeframe: Baseline up to end of treatment (approximately 1.9 years)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| CR | PR | SD | PD | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 0 | 0 | 63 | 38 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 0 | 0 | 50 | 50 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 0 | 6 | 35 | 59 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 0 | 0 | 53 | 47 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 0 | 1 | 53 | 47 |
1 review available for glycine and Lymphoma
| Article | Year |
|---|---|
Heat Shock Proteins in Lymphoma Immunotherapy.
Topics: Animals; Benzamides; Benzodioxoles; Glycine; Heat-Shock Proteins; Humans; Immunotherapy; Immunothera | 2021 |
3 trials available for glycine and Lymphoma
| Article | Year |
|---|---|
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Boron Compounds; | 2018 |
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Topics: Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Boron Compounds; Cross-Over Stud | 2016 |
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gly | 2011 |
20 other studies available for glycine and Lymphoma
| Article | Year |
|---|---|
A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy.
Topics: Cysteine; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Glycine; Glycyrrhetinic Aci | 2020 |
Inhibition of DNA methylation in proliferating human lymphoma cells by immune cell oxidants.
Topics: Cell Proliferation; Cell Survival; Cells, Cultured; Chloramines; DNA Methylation; DNA, Neoplasm; Gly | 2020 |
Occupational exposure to glyphosate and risk of lymphoma:results of an Italian multicenter case-control study.
Topics: Adult; Aged; Case-Control Studies; Female; Glycine; Glyphosate; Herbicides; Humans; Italy; Lymphoma; | 2021 |
Modulating the therapeutic response of tumours to dietary serine and glycine starvation.
Topics: Animals; Antioxidants; Biguanides; Cell Line, Tumor; Diet; Disease Models, Animal; Female; Food Depr | 2017 |
Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.
Topics: Animals; Antineoplastic Agents; Brain Ischemia; Cell Line; Corpus Striatum; Endothelial Cells; Gene | 2014 |
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Body | 2015 |
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening | 2010 |
The conversion of acetate-2-C14 to glycine by cell suspensions of the Gardner lymphosarcoma.
Topics: Acetates; Fabaceae; Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Suspensions | 1955 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
SOME INHIBITORY PROPERTIES OF 6-N-HYDROXYLAMINOPURINE: AN ANALOG OF ADENINE AND HYPOXANTHINE.
Topics: Adenine; Adenine Nucleotides; Animals; Antimetabolites; Carbon Isotopes; Glycine; Guanine Nucleotide | 1964 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. I. The uptake of radioactive glycine into tumor protein.
Topics: Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms; Radioactive Tracers; Sarcoma | 1951 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. III. The rate of radioactive alanine and glycine uptake into the protein of lymphosarcoma cells and normal spleen cells.
Topics: Alanine; Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Radioactive Tracers; Sarcoma; Spleen | 1951 |
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Topics: Animals; Atorvastatin; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Flow Cytomet | 2007 |
Effect of methyl methanesulfonate on macromolecular biosynthesis in P388F cells.
Topics: Alanine; Animals; Culture Techniques; DNA, Neoplasm; Glycine; Lymphoma; Mice; Neoplasm Proteins; Neo | 1967 |
Increased whole-body protein turnover in sick children with newly diagnosed leukemia or lymphoma.
Topics: Ammonia; Glycine; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Nitrogen | 1983 |
In vivo antitumor efficacy of CW252053, a folate-based thymidylate synthase inhibitor.
Topics: Animals; Antineoplastic Agents; Female; Folic Acid Antagonists; Glycine; Lymphoma; Mice; Mice, Inbre | 2001 |
Immunologic effects of arginine supplementation in tumor-bearing and non-tumor-bearing hosts.
Topics: Animals; Arginine; Cytotoxicity, Immunologic; Diet; Dose-Response Relationship, Drug; Glycine; Kille | 1990 |
Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4.
Topics: Adjuvants, Immunologic; Animals; Cytotoxicity Tests, Immunologic; Female; Glycine; Lymphoma; Macroph | 1987 |
A mutational assay system using the thymidine kinase locus in mouse lymphoma cells.
Topics: Animals; Bromodeoxyuridine; Cell Count; Cell Line; Clone Cells; Culture Media; Drug Resistance; Ethy | 1972 |
Purine pyrophosphorylase as a selective genetic marker in a mouse lymphoma, P388, in cell culture.
Topics: Animals; Azaguanine; Clone Cells; Culture Media; Culture Techniques; DNA, Neoplasm; Glycine; Hypoxan | 1966 |